Patients with chronic myeloid leukemia in chronic phase and renal or liver impairment can safely receive frontline dasatinib or nilotinib.

Patients with chronic myeloid leukemia in chronic phase (CML-CP) and mild to moderate renal or liver impairment can safely receive frontline dasatinib or nilotinib and can achieve response rates similar to those without organ dysfunction, a study published in the journal Clinical Lymphoma, Myeloma, & Leukemia has shown.1

There have been limited data on the safety and efficacy of frontline nilotinib and dasatinib in patients with newly diagnosed CML-CP with pre-existing liver and/or renal impairment.

Therefore, researchers sought to analyze the response rates, survival rates, and adverse event rates of 215 patients with CML-CP with or without renal and/or liver dysfunction who had received 1 of the 2 tyrosine kinase inhibitors (TKIs).

The study also demonstrated that patients with baseline renal dysfunction who were treated with dasatinib or nilotinib had a greater incidence of transient reversible acute kidney injury (P = .011 and P < .001, respectively). Further, nilotinib-treated patients with renal insufficiency had a higher risk of bleeding (P < .001).

CancerTherapyAdvisor.com is a free online resource that offers oncology healthcare professionals a comprehensive knowledge base of practical oncology information and clinical tools to assist in making the right decisions for their patients.

Our mission is to provide practice-focused clinical and drug information that is reflective of current and emerging principles of care that will help to inform oncology decisions.